SINOVAC BIOTECH (SVA) CEO Weidong Yin discloses 6.36M-share direct stake

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director and Chief Executive Officer Weidong Yin filed an initial insider ownership report. The filing shows he directly holds 6,359,500 common shares of the company’s stock. This Form 3 reflects his position as a reporting insider rather than a new transaction.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WEIDONG YIN

(Last) (First) (Middle)

NO. 39 SHANGDI XI ROAD

HAIDIAN DISTRICT

(Street)

BEIJING 100085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	6,359,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Weidong Yin’s Form 3 filing for SINOVAC BIOTECH (SVA) show?

The Form 3 shows CEO and director Weidong Yin as a reporting insider who directly holds 6,359,500 common shares of SINOVAC BIOTECH. It establishes his beneficial ownership position without indicating any recent share purchase or sale activity.

How many SINOVAC BIOTECH (SVA) shares does CEO Weidong Yin own?

The filing reports that Weidong Yin directly owns 6,359,500 common shares of SINOVAC BIOTECH. This amount reflects his beneficial ownership position as disclosed on the Form 3 and is used as a baseline for future insider transaction reports.

Does the SINOVAC BIOTECH (SVA) Form 3 show any recent insider buying or selling?

The Form 3 does not report any insider buying or selling activity. Instead, it records Weidong Yin’s existing direct ownership of 6,359,500 common shares, serving as an initial statement of holdings rather than a record of new transactions.

Why is SINOVAC BIOTECH (SVA) CEO Weidong Yin filing a Form 3?

Form 3 is required when someone becomes an insider, such as a director or executive officer. This filing records Weidong Yin’s direct ownership of 6,359,500 SINOVAC BIOTECH common shares, creating a starting point for tracking any future insider transactions.

Is Weidong Yin’s 6,359,500-share position in SINOVAC BIOTECH (SVA) direct or indirect?

The Form 3 identifies Weidong Yin’s ownership as direct, coded as “D” for ownership type. It attributes 6,359,500 common shares directly to him, with no separate indirect holdings or intermediary entities disclosed in this filing excerpt.